A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. This study investigated the activity and tolerability of this combination as first-line therapy in ECOG PS 2 patients. Chemotherapy-naïve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with m...

Descripción completa

Detalles Bibliográficos
Autores principales: MICHAEL, M., PAVLAKIS, N., CLINGAN, P., DE BOER, R., JOHNSTON, M., CLARKE, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583431/
https://www.ncbi.nlm.nih.gov/pubmed/22710607
http://dx.doi.org/10.3892/or.2012.1871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583431/
https://www.ncbi.nlm.nih.gov/pubmed/22710607
http://dx.doi.org/10.3892/or.2012.1871

Ejemplares similares